RESTORING IMMUNE TOLERANCE
CURING DISEASE

Allero Therapeutics develops next generation immunotherapies for allergic and autoimmune disease patients. Its proprietary SOMIT (Specific OroMucosal ImmunoTherapy) technology is designed to induce long-lasting antigen-specific tolerance.​

ABOUT

Allero Therapeutics is a venture-backed, biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders.​

PIPELINE

 

Allero started to develop an R&D pipeline with a focus on a celiac disease product and a food allergy product, and we are looking for other pipeline opportunities to be developed in partnerships.

TECHNOLOGY

 

Based on ideas of the founders, the team has identified a novel specific immunotherapy approach based on antigen-specific tolerance induction.